Literature DB >> 18989671

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Corine Ekhart1, Sjoerd Rodenhuis, Jan H M Schellens, Jos H Beijnen, Alwin D R Huitema.   

Abstract

PURPOSE: The purpose of this study was to determine the potential utility of alternative weight descriptors in the Cockcroft-Gault equation to more accurately predict carboplatin clearance in underweight, normal weight, overweight and obese patients.
METHODS: Clearance values obtained from individual fits using NONMEM were compared to predicted carboplatin clearances calculated using the modified Calvert formula in which creatinine clearance was calculated with the Cockcroft-Gault equation using diverse weight descriptors.
RESULTS: This study indicated that lean body mass was the best weight descriptor in underweight and normal weight patients, while adjusted ideal body weight was the best weight descriptor in overweight and obese patients. However, a flat dose based on the population carboplatin clearance performed better in all weight categories than the use of the Cockcroft-Gault equation with diverse weight descriptors.
CONCLUSION: These results suggest that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, based on the population carboplatin clearance (8.38 l/h = 140 mL/min). Thus, in case an AUC of 5 mg min/mL is desired, the appropriate dose for carboplatin would be 5 x 140 = 700 mg.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989671     DOI: 10.1007/s00280-008-0856-x

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  18 in total

1.  Carboplatin and Liposomal Doxorubicin for Ovarian Cancer.

Authors:  Jamie Nguyen; Dominic A Solimando; J Aubrey Waddell
Journal:  Hosp Pharm       Date:  2016-06

2.  Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer.

Authors:  Julie M Akin; J Aubrey Waddell; Dominic A Solimando
Journal:  Hosp Pharm       Date:  2014-05

3.  Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.

Authors:  Ahmed Hamed Salem; Vincent L Giranda; Nael M Mostafa
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 4.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

5.  Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index.

Authors:  Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

6.  Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance.

Authors:  Melanie White-Koning; Marie Noëlle Paludetto; Félicien Le Louedec; Laurence Gladieff; Christine Chevreau; Etienne Chatelut; Florent Puisset
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-09       Impact factor: 3.333

7.  Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.

Authors:  Ajjai Alva; Stephanie Daignault; David C Smith; Maha Hussain
Journal:  Invest New Drugs       Date:  2013-12-10       Impact factor: 3.850

8.  Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer.

Authors:  E Ryan Pritchard; J Aubrey Waddell; Dominic A Solimando
Journal:  Hosp Pharm       Date:  2015-02

9.  Dosing of chemotherapy in obese and cachectic patients: results of a national survey.

Authors:  Helena Anglada-Martínez; Gisela Riu-Viladoms; Fernando do Pazo-Oubiña; Gloria Molas-Ferrer; Irene Mangues-Bafalluy; Carles Codina-Jané; Natàlia Creus-Baró
Journal:  Int J Clin Pharm       Date:  2014-04-27

10.  Hematological toxicity of carboplatin for gynecological cancer according to body mass index.

Authors:  Fernando Gutierrez; Guillermo Antonio Gonzalez-de-la-Fuente; Gloria Julia Nazco; Juana Oramas; Norberto Batista
Journal:  Eur J Clin Pharmacol       Date:  2016-06-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.